The development of small-molecule inhibitors or activators targeting NSCLC drug sensitivity based on the CRTAC1/RyR/Ca2+/NFAT/STUB1/Akt1 signaling pathway newly elucidated in this study will help guide the implementation of individualized treatment strategies for NSCLC patients. Here, AKT1 is linked to non-small cell lung carcinoma.